Cohance Lifesciences Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 57.3 on March 2024 to 29.3 on March 2023 . This represents a CAGR of -12.55% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 17223 crore on March 2024 to ₹ 12033 crore on March 2023 . This represents a CAGR of -6.92% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Sanjivani Paranteral Ltd?

Market cap of Cohance Lifesciences Ltd is 16,431 Cr while Market cap of Sanjivani Paranteral Ltd is 164 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd?

The stock performance of Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹429.5. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹133.75.

How do dividend payouts of Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.